Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has issued an update.
Shanghai Bio-heart Biological Technology Co., Ltd. announced that its Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System has received approval from China’s National Medical Products Administration for treating resistant hypertension and hypertension patients with drug intolerance. This approval marks a significant milestone for the company, enhancing its market position and potentially impacting stakeholders positively. The Iberis-HTN trial demonstrated the system’s efficacy and safety, showing significant improvements in blood pressure management compared to control groups.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development of medical technology solutions. The company’s primary product is the Iberis® RDN system, which is designed for the treatment of resistant hypertension and hypertension patients with drug intolerance. The company aims to advance its position in the medical technology market through innovative solutions.
YTD Price Performance: 5.49%
Average Trading Volume: 56,982
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$724.1M
For detailed information about 2185 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com